Teachers Advisors LLC boosted its position in Endocyte, Inc. (NASDAQ:ECYT) by 301.8% during the third quarter, Holdings Channel reports. The fund owned 499,762 shares of the biopharmaceutical company’s stock after acquiring an additional 375,389 shares during the period. Teachers Advisors LLC’s holdings in Endocyte were worth $8,876,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in Endocyte during the 3rd quarter valued at about $117,000. Tower Research Capital LLC TRC raised its holdings in Endocyte by 5,461.6% in the third quarter. Tower Research Capital LLC TRC now owns 8,120 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 7,974 shares during the last quarter. Schroder Investment Management Group bought a new stake in shares of Endocyte in the third quarter worth approximately $175,000. HRT Financial LLC bought a new stake in shares of Endocyte in the third quarter worth approximately $211,000. Finally, Kessler Investment Group LLC bought a new stake in shares of Endocyte in the third quarter worth approximately $219,000. 75.62% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages recently issued reports on ECYT. BidaskClub lowered shares of Endocyte from a “buy” rating to a “hold” rating in a research report on Wednesday, November 28th. Zacks Investment Research downgraded shares of Endocyte from a “buy” rating to a “hold” rating in a research note on Wednesday, November 28th. Wedbush downgraded shares of Endocyte from an “outperform” rating to a “neutral” rating in a research note on Thursday, October 18th. Finally, Wells Fargo & Co cut shares of Endocyte from an “outperform” rating to a “market perform” rating in a research report on Friday, October 19th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Endocyte presently has an average rating of “Buy” and a consensus price target of $20.00.
ILLEGAL ACTIVITY NOTICE: This piece was first published by WKRB News and is the property of of WKRB News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.wkrb13.com/2019/02/11/teachers-advisors-llc-acquires-375389-shares-of-endocyte-inc-ecyt.html.
Endocyte Company Profile
Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.
Want to see what other hedge funds are holding ECYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endocyte, Inc. (NASDAQ:ECYT).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.